A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Trial Profile

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs BMS 986205 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Nov 2017 According to a Bristol-Myers Squibb media release, data will be presented at at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
    • 10 Nov 2017 Results published in a Bristol-Myers Squibb Media Release.
    • 24 May 2017 Ipilimumab added to treatments, Planned number of patients changed from 252 to 907, Primary endpoints changed, Trial Focus chnaged from only Adverse events to Adverse events plus Theraprutic.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top